#CVAC

StockTitan

@stocktitan.net

3 months ago

CureVac Announces Voting Results of Extraordinary General Meeting TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of its

#CVAC CureVac Announces Voting Results of Extraordinary General Meeting

www.stocktitan.net/news/CVAC/cure-vac-annou...

StockTitan

@stocktitan.net

3 months ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates {"summary":"","positive":[],"negative":[],"faq":[]}

#CVAC CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

www.stocktitan.net/news/CVAC/cure-vac-annou...

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Small-cap stocks in new ADX downtrend, Thu Nov 6th - #FTFT #GYRE #HTLD #DMLP #CVAC #INGN #JSPR #BHST #KPRX #MXCT #AIOT #WDH #SITC #NPB #NOTE #MED #JBI #DEA #CNMD #BLND #SGN #KAPA #UAVS #VVPR #TRNS #RPD #PSEC - More: crystalequityresearch.com/trade-alerts... - #smallcap

StockTitan

@stocktitan.net

7 months ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac (NASDAQ:CVAC) reported Q2 and H1 2025 financial results and significant business developments. The company entered into a definitive Purchase Agreement with BioNTech for acquisition of all CureVac shares. Additionally, CureVac resolved patent litigation with Pfizer/BioNTech, receiving $740 million plus royalties for COVID-19 vaccine sales.Financial highlights include cash position of €392.7 million as of June 30, 2025, with runway extended into 2028. Revenues decreased to €2.1 million in H1 2025, down 92% year-over-year. Operating loss improved to €116.5 million for H1 2025.In clinical developments, CureVac received CTA clearance from EMA for CVHNLC cancer immunotherapy targeting squamous non-small cell lung cancer, while glioblastoma trial data remains on track for H2 2025.

#CVAC CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

www.stocktitan.net/news/CVAC/cure-vac-annou...

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Small-cap stocks with improving money flow, Tue Jul 8th - #HIFS #GAME #FTFT #CVAC #BWMN #API #CARS #BUR #ARMN #ICCM #LGVN #NBBK #OBLG #PROK #RWAY #SNWV #TLRY #WKHS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

8 months ago

CureVac Announces Voting Results of General Meeting CureVac (NASDAQ:CVAC), a pioneering mRNA-focused biotech company, announced the results of its Annual General Meeting. Shareholders approved all proposals, including key management changes. Axel Sven Malkomes was appointed to the Management Board, while Jean Stéphenne, Debra Barker, Craig A. Tooman, and Klaus Schollmeier were reappointed to the Supervisory Board. Mehdi Shahidi joined as a new Supervisory Board member. Additionally, KPMG Accountants N.V. was reappointed as external auditors for the financial year 2026.

#CVAC CureVac Announces Voting Results of General Meeting

www.stocktitan.net/news/CVAC/cure-vac-annou...

Market Wire News

@marketwirenews.com

9 months ago

Just In: ( NASDAQ: #CVAC ) PRISM Stocks making the biggest premarket moves: Boeing, Oracle, GameStop, Voyager Technologies and more

StockTitan

@stocktitan.net

9 months ago

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac (NASDAQ:CVAC) reported Q1 2025 financial results and business updates. The company received FDA clearance for CVHNLC, its lung cancer candidate, with clinical trials set to begin in H2 2025. Their glioblastoma study CVGBM completed enrollment in Q1 2025, with Phase 2 decision expected in H2 2025. The company maintains a strong cash position of €438.3 million, extending runway into 2028. Q1 2025 showed revenues of €0.9 million, down from €12.4 million in Q1 2024, and an operating loss of €54.7 million, improved from €73.3 million year-over-year. CureVac's core mRNA patents were upheld by the European Patent Office, with an infringement hearing against BioNTech/Pfizer scheduled for July 1, 2025. The company is also advancing its first urinary tract infection vaccine with U.S. IND filing planned for H2 2025.

#CVAC CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

www.stocktitan.net/news/CVAC/cure-vac-annou...

StockTitan

@stocktitan.net

10 months ago

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE CureVac (NASDAQ:CVAC) has secured another favorable ruling from the European Patent Office (EPO) in its ongoing patent litigation against BioNTech SE. The EPO largely dismissed opposition from BioNTech, Pfizer, and others, upholding CureVac's European patent EP 4 023 755 B1 with amended claims. This marks the second positive validity decision for CureVac, following a March 2025 ruling that upheld patent EP 3 708 668 B1. Both patents cover split poly-A tail technology, a foundational invention that enhances medical efficacy by improving protein expression in mRNA constructs. A hearing on the infringement of both patents is scheduled for July 1, 2025, at the Regional Court Düsseldorf. A favorable infringement decision would trigger damage assessment proceedings.

#CVAC CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

www.stocktitan.net/news/CVAC/cure-vac-recei...

StockTitan

@stocktitan.net

11 months ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025Filed IND and CTA

#CVAC CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

www.stocktitan.net/news/CVAC/cure-vac-annou...

StockTitan

@stocktitan.net

11 months ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer CureVac (Nasdaq: CVAC) has received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 1 clinical trial of CVHNLC in squamous non-small cell lung cancer (sqNSCLC) patients. CVHNLC is an mRNA-based precision immunotherapy encoding eight tumor-associated antigens.The trial will evaluate CVHNLC in combination with pembrolizumab, featuring two parts: Part A: dose-escalation study (100μg to 400μg) as first-line maintenance treatmentPart B: optional dose expansion testing CVHNLC with first-line chemotherapy and pembrolizumabPrimary endpoints include dose-limiting toxicities and treatment-related adverse events, while secondary endpoints cover overall response rate, progression-free survival, and disease control rate. Patient treatment is expected to begin in the second half of 2025, with additional oncology candidates planned for clinical trials in 2026.

#CVAC CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

www.stocktitan.net/news/CVAC/cure-vac-recei...

StockTitan

@stocktitan.net

11 months ago

Major Patent Victory: CureVac's Critical mRNA Technology Upheld Against BioNTech Challenge European Patent Office validates CureVac's crucial mRNA technology patent despite BioNTech's opposition. Landmark decision strengthens position ahead of 2025 infringement case.

#CVAC CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

www.stocktitan.net/news/CVAC/cure-vac-recei...

@z0th.bsky.social

1 year ago

Cambodian man dies from bird flu A 28-year-old Cambodian man died from bird flu on Friday after eating sick chickens, the health ministry said.

28 yead old dies of bird flu. Is the bird flu stock rally over? #birdflu #nvax #mrna #vrax #cvac
medicalxpress.com/news/2025-01...

Rolling Returns

@rollingreturns.bsky.social

1 year ago

📊 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐤𝐞𝐫𝐬 𝐒𝐭𝐨𝐜𝐤𝐬 𝐒𝐨𝐚𝐫𝐢𝐧𝐠🟢

Shares of vaccine makers skyrocketed Tuesday after U.S. health officials confirmed the first H5N1 bird flu death in the U.S.

💉 #MRNA +13.27%
💉 #NVAX +12.81%
💉 #CVAC +7.43%

#QQQ #SPY #ES_F #NQ_F

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #CVAC ) CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #CVAC ) CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

#StockMarket #News